Login to Your Account



ASCO 2013

Gilead Data Suggest Targeted Cancer Drugs Coming of Age

By Marie Powers
BioWorld Today Staff Writer

Monday, May 20, 2013

Gilead Science Inc.'s oral targeted cancer drug, idelalisib (GS-1101), made a splash last week when the American Society of Clinical Oncology (ASCO) unveiled thousands of abstracts scheduled for presentation at next week's annual meeting in Chicago. In a press conference Wednesday afternoon, Jennifer R. Brown, director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute, provided Phase I findings suggesting idelalisib, as a single agent, has the potential to stave off the need for additional treatments for relapsed/refractory chronic lymphocytic leukemia (CLL).

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription